Compare WKEY & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKEY | PLRX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | Switzerland | United States |
| Employees | 102 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.5M | 74.9M |
| IPO Year | N/A | 2020 |
| Metric | WKEY | PLRX |
|---|---|---|
| Price | $8.11 | $1.23 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 4 |
| Target Price | ★ $10.50 | $2.67 |
| AVG Volume (30 Days) | 85.8K | ★ 463.6K |
| Earning Date | 01-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.22 | N/A |
| Revenue Next Year | $91.39 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.28 | $1.09 |
| 52 Week High | $19.80 | $1.95 |
| Indicator | WKEY | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 59.76 | 48.03 |
| Support Level | $7.39 | $1.14 |
| Resistance Level | $8.22 | $1.37 |
| Average True Range (ATR) | 0.58 | 0.06 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 65.40 | 38.64 |
WISeKey International Holding Ltd is a cybersecurity company focused on delivering integrated security solutions for the Internet of Things and digital identity ecosystems. It integrates secure semiconductors, cybersecurity software, and a globally recognized Root of Trust (RoT) into products and services that protect users, devices, data and transactions in the internet-connected world. It has two business segments. The IoT segment, which is the key revenue driver, generates revenue from the sale of semiconductor's secure chips. The mPKI segment generates revenues from Digital Certificates, It derives maximum revenue from IoT segment.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.